STAGE III COLON CANCER AJCC V8
Clinical trials for STAGE III COLON CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III COLON CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III COLON CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy combo shows promise in High-Risk colon cancer trial
Disease control OngoingThis study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help prevent colon cancer from returning after surgery. It includes 712 people with stage III colon cancer that has a specific DNA repair problem (dMMR). The main goal is to see if th…
Matched conditions: STAGE III COLON CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 17, 2026 02:58 UTC
-
New drug cocktail shows promise for Tough-to-Treat colorectal cancer
Disease control OngoingThis study tests a combination of three drugs (cetuximab, LY3214996, and abemaciclib) in people with advanced colorectal cancer that has spread and no longer responds to standard therapy. The goal is to see if the combination can shrink tumors and improve survival. About 46 adult…
Matched conditions: STAGE III COLON CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 17, 2026 02:56 UTC
-
New drug combo targets Hard-to-Treat HER2 cancers
Disease control OngoingThis early-stage study tests a combination of two drugs—trastuzumab deruxtecan (DS-8201a) and ceralasertib—in people with advanced solid tumors that have a HER2 mutation. The first part finds the safest dose and checks side effects. The second part compares the combo to DS-8201a …
Matched conditions: STAGE III COLON CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
New combo therapy targets hard-to-treat colorectal cancer
Disease control OngoingThis study tests a new drug, SX-682, alone and with the immunotherapy nivolumab, in people with a specific type of advanced colorectal cancer that has spread or cannot be removed. The cancer must have a RAS mutation and be microsatellite stable (MSS), which often makes it harder …
Matched conditions: STAGE III COLON CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
Immunotherapy combo shows promise for Hard-to-Treat colorectal cancer
Disease control OngoingThis study looks at whether adding an immunotherapy drug (nivolumab) to the usual two-drug treatment can better shrink tumors in people with a specific type of advanced colorectal cancer (BRAF-mutated, microsatellite stable). About 86 adults whose cancer has spread or can't be re…
Matched conditions: STAGE III COLON CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
New drug cocktail aims to stop BRAF colon cancer in its tracks
Disease control OngoingThis study tests whether adding two targeted drugs (encorafenib and cetuximab) after standard surgery and chemotherapy can lower the chance of cancer coming back in people with a specific genetic type of stage II/III colon cancer (BRAF V600E). Participants either receive the drug…
Matched conditions: STAGE III COLON CANCER AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 26, 2026 12:00 UTC
-
Cancer treatment costs under the microscope: new study tracks financial toll
Knowledge-focused OngoingThis study follows 565 people with stage I-III colon or rectal cancer to understand how treatment affects their finances and quality of life. Participants complete surveys about costs and financial well-being over 12 months. The goal is to help doctors better support patients fac…
Matched conditions: STAGE III COLON CANCER AJCC V8
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Jun 16, 2026 12:51 UTC